Compare Alcon AG (ALC) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Altria Group Inc — how do they compare? Alcon AG trades at $66.71 (market cap $32.69B), while Altria Group Inc trades at $73.43 (market cap $121.84B). The key difference: Altria Group Inc is far larger — about 3.7× Alcon AG's market cap, and Altria Group Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals.
| ALC | MO | |
|---|---|---|
Market Cap | $32.69B | $121.84B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $74.55 |
52-Week Low | $62.02 | $54.72 |
Enterprise Value | $36.28B | $142.91B |
Dividend Yield | 0.54% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
MO trades at $72.96, up 0.34% today, with a bullish technical signal from moving averages and a neutral RSI near 60. The stock shows strong profitability with a 39.52% net margin and consistent cash flow, though revenue has been flat near $20.1B. Analysts are largely positive, with 62% recommending Buy and a consensus target of $70.75. Recent news highlights its appeal as a dividend king for income investors, with a $1.06 dividend paid in July 2026.
Outlook: MO offers stable income with high margins and dividend reliability, but faces risks from debt levels and regulatory pressures. The stock is near analyst targets, suggesting limited upside, yet remains a defensive hold for yield-seeking portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
